close
MENU
Hot Topic EARNINGS
Hot Topic EARNINGS
Margin Call
5 mins to read

Ryman looks like a classic value trap

ANALYSIS: If you think a company must be ‘value’ because its share price is down 50%, look again.

Ryman was clearly an in-favour NZX listed business as 2020 began.

It is a fact that Ryman Healthcare enjoyed a stellar run from 2009 to 2020, up nearly 1800% from 85c to $16. It can also be readily assumed that a bunch of investors made good money from holding Ryman over parts of this 10-year period. Sustained periods of strong returns that create investors

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

NZ$399.00 / yearly

Offer ends March 31st

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Subscription

NZ$29.95 / monthly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Stephen Bennie Tue, 07 Feb 2023
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Ryman looks like a classic value trap
Margin Call,
97528
true